Four hundred sixty-six female patients were enrolled in a randomized study that compared the clinical efficacies of single oral doses of cefuroxime axetil and amoxicillin with probenecid in the treatment of uncomplicated gonorrhea. Two hundred ninety-five patients had culture-positive gonococcal infections and completed the investigation. Cure rates for the patients treated with cefuroxime axetil and those treated with amoxicillin with probenecid were high (>95%) for genitorectal infections. Pharyngeal infections, however, were not uniformly eradicated by either cefuroxime axetil (60%) or amoxicillin with probenecid (64%). Approximately 13% of each patient group suffered adverse events, which were gastrointestinal in the majority and were transient. Compared with amoxicillin plus probenecid, cefuroxime axetil in a single oral dose was an equally safe and effective drug for the treatment of uncomplicated gonorrhea in women caused by penicillin-susceptible strains.
Earlier studies (3, 4, 8-10, 12, 14, 16) examining the treatment of uncomplicated gonorrhea with a single dose of parenteral cefuroxime with and without oral probenecid demonstrated that this regimen was efficacious and well tolerated. Cefuroxime axetil, the ester prodrug of cefuroxime, was also shown to be effective (2, 5, 13, 18) in the treatment of uncomplicated gonorrhea when administered in a single oral dose, with and without probenecid. Although these investigations with cefuroxime axetil provided much information on the treatment of urethral infections in men, the studies enrolled relatively few women. We therefore examined the efficacy of single-dose cefuroxime axetil in a large number of women with uncomplicated gonorrhea who were seen at sexually transmitted disease clinics of four different city or county health departments.
(This work was presented in part at the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, 4 None of the gonococcal isolates that accounted for the microbiologic failures in patients treated with either of the two drug regimens was resistant to penicillin, ampicillin, or cefuroxime in in vitro susceptibility testing with disk diffusion. Three of the gonococcal isolates from patients who were microbiologically cured with either cefuroxime axetil (n = 2) or amoxicillin with probenecid (n = 1) demonstrated penicillinase production, whereas no chromosomally mediated penicillin resistance was found among the gonococcal isolates.
The drugs were well tolerated, with approximately 13% of patients in each treatment group reporting adverse events (Table 3) . Various gastrointestinal reactions, such as nausea, vomiting, diarrhea, upset stomach, and abdominal pain, accounted for more than three-quarters of these complaints. Other events in both treatment groups included vaginitis, rash or pruritis, shortness of breath, dizziness, sleepiness or fatigue, headache, and fainting. (3, 4, 8-10, 12, 14, 16) demonstrated the efficacy of parenteral cefuroxime in the treatment of uncomplicated gonorrhea, Reichman and colleagues (13) used a single oral dose of cefuroxime axetil with and without probenecid in a randomized study of 184 patients with uncomplicated gonorrhea. They employed three treatment regimens which included (i) cefuroxime axetil (1 g), (ii) cefuroxime axetil (1 g) with probenecid, and (iii) amoxicillin (3 g) with probenecid. Cure rates in the treatment groups were 98, 98, and 96%, respectively. Only 2% of patients who received cefuroxime axetil alone complained of nausea, as compared with 11% of those who received either regimen that contained probenecid (P < 0.05). With only 29 women enrolled in the study, the efficacy of oral cefuroxime axetil in the therapy of uncomplicated gonorrhea in women was not as well established as that for men.
Three different studies (2, 5, 18 ) published 1 year later supported the clinical impression that cefuroxime axetil was as efficacious and as safe as standard therapy with either ampicillin or amoxicillin with probenecid. However, only 40 (11.6%) of the 346 patients examined in the three drug trials were women. Moreover, one of the investigations (5) included men exclusively.
Before the present survey, only a small number of patients treated in the four published cefuroxime axetil comparison trials (2, 5, 13, 18) manifested rectal gonococcal infections. One study (2) entered no patients with rectal infections, and another survey (18) did not distinguish numbers of patients with either rectal or pharyngeal infections. Since only 8 of 129 patients in the latter study (18) harbored infections at sites other than the cervix or urethra, recommendations with regard to the treatment of gonococcal infections of the rectum and pharynx were precluded. Only 13 patients with rectal infections were evaluated in the two remaining studies (5, 13) . Five of seven patients given cefuroxime axetil alone were cured, whereas all six patients treated with both cefuroxime axetil and probenecid were successfully treated.
Of 54 women with rectal gonococcal infections treated with cefuroxime axetil, 53 (98.2%) were cured. In addition, over 97% of patients treated with the amoxicillin-probenecid regimen had rectal infection eliminated.
As seen in the present investigation, pharyngeal gonococcal infections are usually more difficult to eradicate as compared with genitorectal infections (6) . To control the spread of N. gonorrhoeae, identifying therapeutic regimens effective in eradicating gonococci from the oropharynx seems appropriate (6) . At the same time, pharyngeal infections are usually asymptomatic (6, 17, 20) , undergo spontaneous cure (6, 17) , and are considered by some as unusual sources of transmission of N. gonorrhoeae (17, 19) .
Several statements seem appropriate concerning the use of cefuroxime axetil for the treatment of uncomplicated gonorrhea. First, cefuroxime axetil is as effective and safe as amoxicillin with probenecid for the therapy of cervical, urethral, and rectal infections in women. Second, cefuroxime axetil, like amoxicillin with probenecid, is much less efficacious for the treatment of gonococcal pharyngeal infections. Third, the role of cefuroxime axetil in the treatment of infections caused by penicillinase-producing N. gonorrhoeae remains to be established, since only three women in this study were infected with penicillinase-producing strains. At the same time, in vitro susceptibility data (7, 11, 15) , reports of small numbers of successfully treated cases (18) (including the two women in the present series treated with cefuroxime axetil), and previously demonstrated efficacy of parenteral cefuroxime therapy suggest that cefuroxime axetil may be effective against infections due to penicillinaseproducing N. gonorrhoeae and deserves further evaluation.
